Linked Life Data

19052740

Source:http://linkedlifedata.com/resource/pubmed/id/19052740

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2009-5-26
pubmed:abstractText
Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy. However, few tumor associated antigens (TAA), which can be targeted by immunotherapy, have been identified for this type of cancer. von Hippel-Lindau clear cell RCC (VHL(-/-)RCC) are characterized by mutations in the VHL tumor suppressor gene. Loss of VHL function causes the overexpression of transforming growth factor (TGF)-alpha, leading us to hypothesize that TGF-alpha could be a potential TAA for immunotherapy of kidney cancer, which was evaluated in this study.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1432-0851
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1207-18
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
TGF-alpha as a candidate tumor antigen for renal cell carcinomas.
pubmed:affiliation
Department of Medicine, CRCHUM-Hôpital Notre-Dame, Université de Montréal, Montreal, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't